Intrexon Announces Proposed Public Offering of Common Stock

Intrexon Corporation

, a leader in synthetic biology, announced today it has commenced an underwritten public offering of up to $150 million of shares of its common stock. Intrexon intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of the common stock offered in the public offering. All of the shares in the offering will be sold by Intrexon. Intrexon Corporation logo. J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. Jefferies is acting as a lead manager for the offering. Griffin Securities and Mizuho Securities are acting as co-managers for the offering. The offering is subject to market and other conditions and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments. The public offering will be made pursuant to an automatic shelf registration statement on Form S-3ASR that was previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and will be available on the SEC's website at www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from J.P. Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: +1 (866) 803-9204 or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, email dg.prospectus_requests@baml.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.